Mutation News and Research

RSS

AVMA confirms that a household cat in Iowa showed signs of H1N1 influenza

Amarillo Biosciences, Inc. reported that the American Veterinary Medical Association (AVMA) recently confirmed that a household cat in Iowa developed signs of respiratory infection caused by H1N1 influenza virus.

12 Nov 2009

Stapled Peptides can inhibit key intracellular biological targets, says new research

Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex." Results presented in the paper showed that Stapled Peptides can potently and directly inhibit the transcription factor Notch, an oncogene implicated in cancer cell proliferation and survival.

12 Nov 2009

Hand washing: Best method for killing germs and protecting oneself from flu

Fears of contracting the H1N1 virus this flu season have people steering clear of strangers with coughs and scolding friends who don't sneeze into their crooked elbows. With everyone trying to stay germ free, hand sanitizer has become a popular means of protection. But although a quick pump from a Purell dispenser is the most convenient form of hand cleaning, is it the best?

11 Nov 2009

AMP's four-day event on the latest advances in clinical molecular diagnostics

The Association for Molecular Pathology (AMP) invites the media to follow its upcoming 2009 Annual Meeting and Exhibits and learn about the latest advances in clinical molecular diagnostics.

10 Nov 2009

Activating TAp63 protein, a viable anti-cancer strategy

Oncologists have had their hands tied because more than half of all human cancers have mutations that disable a protein called p53. As a critical anti-cancer watchdog, p53 masterminds several cancer-fighting operations within cells. When cells lose p53, tumors grow aggressively and often cannot be treated.

10 Nov 2009

TessArae introduces new integrated product solutions for testing human genetic disease

TessArae® LLC, a global leader in resequencing microarray-based applications, announces the launch of new integrated product solutions for genetic testing of the mutations that underlie human hereditary diseases. The combination of TessArae's expertise in microarray-based resequencing with novel nucleotide sequence basecalling algorithms and analysis software enables screening for all targeted mutations in multiple genes of a syndrome or disorder simultaneously.

10 Nov 2009

FDA accepts ChemGenex Pharmaceuticals' NDA for Omapro

ChemGenex Pharmaceuticals Limited announced today that the U.S. Food & Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for Omapro™ (omacetaxine mepesuccinate) for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.

10 Nov 2009

NanoViricides to present data on its in vivo studies against influenza

NanoViricides, Inc., announced today that the Company’s CEO, Eugene Seymour, MD, MPH, has been invited to participate in a panel discussion at the Influenza Congress USA 2009, in Washington DC on November 19th (www.terrapinn.com/usaflu). The discussion will center on the “Evolving Role of Anti-Virals” in influenza treatment.

9 Nov 2009

TNS files Provisional Use Patent application on the ability of a natural organic mushroom formula

Total Nutraceutical Solutions, Inc. (TNS), announced that it has filed a Provisional Use Patent application on the ability of a proprietary natural organic mushroom formula to control oxidative stress.

9 Nov 2009

Research reveals new biological function of polycystins in regulating pressure sensing

What is the role of proteins called polycystins in patients with polycystic kidney disease? A team of researchers from CNRS and INSERM, led by Eric Honoré from the Institut de Pharmacologie Moléculaire et Cellulaire (IPMC, Université de Nice Sophia Antipolis/CNRS) has elucidated the molecular and cellular mechanisms linked to polycystin malfunctions that cause this common hereditary disease.

6 Nov 2009

Landmark meeting discusses goal of detecting Alzheimer disease before symptoms appear

This past October, 214 researchers from the U.S., Europe, and Australia, as well as representatives of families with aggressive genetic forms of Alzheimer disease (AD), met at Washington University, St. Louis, Missouri, to devote two intense days of talks and discussion to their goal of detecting this disease before symptoms appear. By a growing consensus, defining the "silent" phase of AD has become the field's central challenge if it is to modernize drug testing and lay the groundwork for AD prevention trials.

6 Nov 2009

Long QT syndrome study reveals importance of genetic testing's role in diagnosing disease

Results of a long QT syndrome (LQTS) study published in the current issue of Circulation play an important role in understanding genetic testing's role in diagnosing disease, according to the senior author, Michael Ackerman, M.D., Ph.D. A pediatric cardiologist at Mayo Clinic, Dr. Ackerman directs Mayo's Long QT Syndrome Clinic and is the director of the Mayo Clinic Windland Smith Rice Sudden Death Genomics Laboratory.

6 Nov 2009

Arthur H. Rubenstein to receive the Abraham Flexner Award

Arthur H. Rubenstein, MBBCh, Executive Vice President of the University of Pennsylvania for the Health System, and Dean, School of Medicine, will receive the Abraham Flexner Award for Distinguished Service to Medical Education from the Association of American Medical Colleges (AAMC).

6 Nov 2009

Amgen announces the results for Phase 3 PRIME '203' trial of Vectibix

Amgen today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.

5 Nov 2009

New therapeutic approach targets cancer cells, not normal cells

The ultimate goal in cancer research, a treatment that kills cancer cells whilst leaving healthy cells untouched, is brought nearer by the success of a new therapeutic approach. The potential therapy, published in BioMed Central's open access journal Breast Cancer Research, targets proliferation of cancer, but not normal, cells.

5 Nov 2009

Tetracycline-like compound raises hope for treatment of spinal muscular atrophy

A chemical cousin of the common antibiotic tetracycline might be useful in treating spinal muscular atrophy (SMA), a currently incurable disease that is the leading genetic cause of death in infants. This is the finding of a research collaboration involving Adrian Krainer, Ph.D., of Cold Spring Harbor Laboratory (CSHL) and scientists from Paratek Pharmaceuticals and Rosalind Franklin University of Medicine and Science.

5 Nov 2009

USPTO awards Peregrine Pharmaceuticals patent for anti-viral uses of phosphatidylserine targeting antibodies

Peregrine Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,611,704, which includes broad claims covering anti-viral uses of phosphatidylserine (PS)-targeting antibodies including Peregrine's lead clinical compound, bavituximab. PS is a unique marker exposed on the surface of virally infected cells that can be targeted to treat a broad spectrum of virus infections.

5 Nov 2009

Researchers use fruit fly model for diabetes research

As rates of obesity, diabetes, and related disorders have reached epidemic proportions in the US in recent years, scientists are working from many angles to pinpoint the causes and contributing factors involved in this public health crisis. While sedentary lifestyles and diets high in sugar and fat contribute significantly to the rise in diabetes rates, genetic factors may make some people more vulnerable than others to developing diabetes.

4 Nov 2009

Leprosy: Man's persistent companion

For thousands of years an undesirable and persistent companion has been travelling with man wherever he goes. Mycobacterium leprae, the bacterium that causes leprosy, has only one known natural host - mankind.

4 Nov 2009

Sigma-Aldrich, Polyplus-transfection sign licensing agreement to manufacture ZNA oligonucleotides

Sigma-Aldrich today announced a worldwide licensing agreement with Polyplus-transfection (Strasbourg, France) to manufacture and commercialize Zip Nucleic Acid (ZNA(TM)) oligonucleotides, a new technology that provides solutions for increased affinity for nucleic acids.

3 Nov 2009

Mutation News and Research

AVMA confirms that a household cat in Iowa showed signs of H1N1 influenza

Stapled Peptides can inhibit key intracellular biological targets, says new research

Hand washing: Best method for killing germs and protecting oneself from flu

AMP's four-day event on the latest advances in clinical molecular diagnostics

Activating TAp63 protein, a viable anti-cancer strategy

TessArae introduces new integrated product solutions for testing human genetic disease

FDA accepts ChemGenex Pharmaceuticals' NDA for Omapro

NanoViricides to present data on its in vivo studies against influenza

TNS files Provisional Use Patent application on the ability of a natural organic mushroom formula

Research reveals new biological function of polycystins in regulating pressure sensing

Landmark meeting discusses goal of detecting Alzheimer disease before symptoms appear

Long QT syndrome study reveals importance of genetic testing's role in diagnosing disease

Arthur H. Rubenstein to receive the Abraham Flexner Award

Amgen announces the results for Phase 3 PRIME '203' trial of Vectibix

New therapeutic approach targets cancer cells, not normal cells

Tetracycline-like compound raises hope for treatment of spinal muscular atrophy

USPTO awards Peregrine Pharmaceuticals patent for anti-viral uses of phosphatidylserine targeting antibodies

Researchers use fruit fly model for diabetes research

Leprosy: Man's persistent companion

Sigma-Aldrich, Polyplus-transfection sign licensing agreement to manufacture ZNA oligonucleotides

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News